1887

Abstract

The susceptibility to teicoplanin, vancomycin and linezolid of 30 clinical isolates of was tested by Vitek 2, Phoenix, Etest, broth microdilution and disc diffusion tests. The and resistance genes and the 23S rRNA gene G2576T mutation were detected by PCR and PCR-RFLP, respectively. Resistance rates to teicoplanin ranged from 3 % for Vitek 2 to 57.6 % for the Phoenix test, and those to vancomycin ranged from 56.7 % for Vitek 2 to 86.7 % for the Phoenix test. Only two out of 25 strains carrying the gene were univocally recognized as the VanA phenotype. The only strain with the G2576T mutation did not carry the gene and showed resistance to linezolid by the disc diffusion, Vitek 2 and broth dilution methods (MIC >8 μg ml), but was susceptible when tested with the Phoenix test and Etest (MIC ≤4 μg ml). Therefore, the resistance to glycopeptides and linezolid was not univocally detected by the susceptibility testing methods used in this study.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.016444-0
2010-06-01
2019-10-13
Loading full text...

Full text loading...

/deliver/fulltext/jmm/59/6/672.html?itemId=/content/journal/jmm/10.1099/jmm.0.016444-0&mimeType=html&fmt=ahah

References

  1. Abele-Horn, M., Hommers, L., Trabold, R. & Frosch, M. ( 2006; ). Validation of VITEK 2 version 4.01 software for detection, identification, and classification of glycopeptides-resistant enterococci. J Clin Microbiol 44, 71–76.[CrossRef]
    [Google Scholar]
  2. Alam, M. R., Donabedian, S., Brown, W., Gordon, J., Chow, J. W., Zervos, M. J. & Hershberger, E. ( 2001; ). Heteroresistance to vancomycin in Enterococcus faecium. J Clin Microbiol 39, 3379–3381.[CrossRef]
    [Google Scholar]
  3. Biedenbach, D. J., Moet, G. J. & Jones, R. N. ( 2004; ). Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997–2002). Diagn Microbiol Infect Dis 50, 59–69.[CrossRef]
    [Google Scholar]
  4. Bonora, M. G., Solbiati, M., Stepan, E., Zorzi, A., Luzzani, A., Catania, M. R. & Fontana, R. ( 2006; ). Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage. J Clin Microbiol 44, 1153–1155.[CrossRef]
    [Google Scholar]
  5. Clark, N. C., Cooksey, R. C., Hill, B. C., Swenson, J. M. & Tenover, F. C. ( 1993; ). Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrob Agents Chemother 37, 2311–2317.[CrossRef]
    [Google Scholar]
  6. CLSI ( 2006; ). Performance Standards for Antimicrobial Susceptibility Tests; Approved Standard, 9th edn, M2-A9. Wayne, PA: Clinical and Laboratory Standards Institute.
  7. CLSI ( 2007; ). Performance Standards for Antimicrobial Susceptibility Testing; 17th Informational Supplement, M100-S17. Wayne, PA: Clinical and Laboratory Standards Institute.
  8. Deshpande, L. M., Fritsche, T. R., Moet, G. J., Biedenbach, D. J. & Jones, R. N. ( 2007; ). Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 58, 163–170.[CrossRef]
    [Google Scholar]
  9. Donabedian, S., Hershberger, E., Thal, L. A., Chow, J. W., Clewell, D. B., Robinson-Dunn, B. & Zervos, M. J. ( 2000; ). PCR fragment length polymorphism analysis of vancomycin-resistant Enterococcus faecium. J Clin Microbiol 38, 2885–2888.
    [Google Scholar]
  10. Falagas, M. E. & Vardakas, K. Z. ( 2008; ). Benefit–risk assessment of linezolid for serious Gram-positive bacterial infections. Drug Saf 31, 753–768.[CrossRef]
    [Google Scholar]
  11. Garcia-Garrote, F., Cercenado, E. & Bouza, E. ( 2000; ). Evaluation of a new system, VITEK 2, for identification and antimicrobial susceptibility testing of enterococci. J Clin Microbiol 38, 2108–2111.
    [Google Scholar]
  12. Gonzales, R. D., Schreckenberger, P. C., Graham, M. B., Kelkar, S., DenBesten, K. & Quinn, J. P. ( 2001; ). Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357, 1179 [CrossRef]
    [Google Scholar]
  13. Jones, R. N., Fritsche, T. R., Sader, H. S. & Ross, J. E. ( 2007; ). LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centres). Diagn Microbiol Infect Dis 59, 309–317.[CrossRef]
    [Google Scholar]
  14. Kobayashi, I., Muraoka, H., Iyoda, T., Nishida, M., Hasegawa, M. & Yamaguchi, K. ( 2004; ). Antimicrobial susceptibility testing of vancomycin-resistant Enterococcus by the Vitek system, and comparison with two NCCLS reference methods. J Med Microbiol 53, 1229–1232.[CrossRef]
    [Google Scholar]
  15. Lee, W. G., Huh, J. Y., Cho, S. R. & Lim, Y. A. ( 2004; ). Reduction in glycopeptide resistance in vancomycin-resistant enterococci as a result of vanA cluster rearrangements. Antimicrob Agents Chemother 48, 1379–1381.[CrossRef]
    [Google Scholar]
  16. Linden, P. K. ( 2002; ). Treatment options for vancomycin-resistant enterococcal infections. Drugs 62, 425–441.[CrossRef]
    [Google Scholar]
  17. Marshall, S. H., Donskey, C. J., Hutton-Thomas, R., Salata, R. A. & Rice, L. B. ( 2002; ). Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 46, 3334–3336.[CrossRef]
    [Google Scholar]
  18. NNIS ( 2001; ). National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992–June 2001, issued August 2001. Am J Infect Control 29, 404–421.[CrossRef]
    [Google Scholar]
  19. Park, I. J., Lee, W. G., Shin, J. H., Lee, K. W. & Woo, G. J. ( 2008; ). VanB phenotype-vanA genotype Enterococcus faecium with heterogeneous expression of teicoplanin resistance. J Clin Microbiol 46, 3091–3093.[CrossRef]
    [Google Scholar]
  20. Pendle, S., Jefts, P., Olma, T., Su, Y., Gilroy, N. & Gilbert, G. L. ( 2008; ). Difficulties in detection and identification of Enterococcus faecium with low-level inducible resistance to vancomycin, during a hospital outbreak. Clin Microbiol Infect 14, 853–857.[CrossRef]
    [Google Scholar]
  21. Rice, L. B., Hutton-Thomas, R., Lakticova, V., Helfand, M. S. & Donskey, C. J. ( 2004; ). β-Lactam antibiotics and gastrointestinal colonization with vancomycin-resistant enterococci. J Infect Dis 189, 1113–1118.[CrossRef]
    [Google Scholar]
  22. Ruggero, K. A., Schroeder, L. K., Schreckenberger, P. C., Mankin, A. S. & Qiunn, J. P. ( 2003; ). Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs. Diagn Microbiol Infect Dis 47, 511–513.[CrossRef]
    [Google Scholar]
  23. Scheetz, M. H., Qi, C., Noskin, G. A, Warren, J. R., Postelnick, M. J., Malczynski, M., Huang, J. & Zembower, T. R. ( 2006; ). The clinical impact of linezolid susceptibility reporting in patients with vancomycin-resistant enterococci. Diagn Microbiol Infect Dis 56, 407–413.[CrossRef]
    [Google Scholar]
  24. Tenover, F. C., Williams, P. P., Stocker, S., Thompson, A., Clark, L. A., Limbago, B., Carey, R. B., Poppe, S. M., Shinabarger, D. & McGowan, J. E., Jr ( 2007; ). Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci. J Clin Microbiol 45, 2917–2922.[CrossRef]
    [Google Scholar]
  25. Thal, L.-A., Donabedian, S., Robinson-Dunn, B., Chow, J. W., Dembry, L., Clewell, D. B., Alshab, D. & Zervos, M. J. ( 1998; ). Molecular analysis of glycopeptide-resistant Enterococcus faecium isolates collected from Michigan hospitals over a 6-year period. J Clin Microbiol 36, 3303–3308.
    [Google Scholar]
  26. van den Braak, N., Goessens, W., van Belkum, A., Verbrugh, H. A. & Endtz, H. P. ( 2001; ). Accuracy of the VITEK 2 system to detect glycopeptides resistance in enterococci. J Clin Microbiol 39, 351–353.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.016444-0
Loading
/content/journal/jmm/10.1099/jmm.0.016444-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error